Questionnaire on switching from the tiotropium HandiHaler to the Respimat inhaler in patients with chronic obstructive pulmonary disease: changes in handling and preferences immediately and several years after the switch

BACKGROUND: Tiotropium (Spiriva) is an inhaled muscarinic antagonist for patients with chronic obstructive pulmonary disease (COPD), and is available in two forms: the HandiHaler and the Respimat inhaler. The aim of this study was to investigate the handling of and preference for each device immedia...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanada, Soichiro, Wada, Shota, Ohno, Takeshi, Sawaguchi, Hirochiyo, Muraki, Masato, Tohda, Yuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4293296/
https://www.ncbi.nlm.nih.gov/pubmed/25609941
http://dx.doi.org/10.2147/COPD.S73521

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4293296/
https://www.ncbi.nlm.nih.gov/pubmed/25609941
http://dx.doi.org/10.2147/COPD.S73521

Ejemplares similares